A Phase 3 interventional study of VLA15 and Normal Saline in Lyme Disease, sponsored by Pfizer. Completed at 65 sites in United States. Open to participants aged 5 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Pfizer · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.
Among the 54 studies in Lyme Disease with a site in United States, this one is the 3rd largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2022, is one of 10 in phase 3, and was the 42nd registered.
98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.
Browse Lyme Disease studies →15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 7+ · Healthy volunteers
Columbia University · Sites in United States
Ages 18–70
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Children's National Research Institute · Sites in United States
Ages 18+ · Women only
Children's National Research Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 10
First in 1996; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,547 is above the median of 120 across 52 interventional studies indexed under Lyme Disease.
Median enrollment 72 across the 33 interventional studies, 410 across the 21 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 54 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Lyme Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Lyme Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500506Phase 3PfizerA Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | 2026-12-04 |
| NCT05776251Columbia UniversitytaVNS for Persistent Symptoms From Lyme Disease | 2026-11 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06511050Icahn School of Medicine at Mount SinaiLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2026-12 |
| NCT06397794Children's National Research InstituteNavigating Pregnancy and Parenthood With Lyme Disease | 2026-12-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 54 studies in Lyme Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to understand if the study vaccine (called VLA15) is safe in healthy children.
We are looking for children who:
Lyme disease happens most often in children of this age. The study vaccine may be used potentially to help prevent Lyme disease. The goal of this study is to get more information about the safety of the study vaccine in this age group.
Participants will be in this study for about 2 years. During that time, they will receive VLA15 or placebo (sterile saltwater solution) by a "shot" in the arm. We will compare experience of children receiving VLA15 to those receiving the placebo. Participants will not know whether they get VLA15 or placebo.
Everyone participating in this study will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 6-valent OspA-based Lyme disease vaccine (VLA15).
Biological: VLA15
Participants will receive 0.9% sodium chloride solution for injection
Other: Normal Saline
6-valent OspA-based Lyme disease vaccine
Also known as: PF-07307405
0.9% sodium chloride solution for injection
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the electronic dairy (e-diary) or by investigators in case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on Center for Biologics Evaluation and Research (CBER) toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 2
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 3
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study Vaccination
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after any study vaccination
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 1
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 2
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 3
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study Vaccination
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after any study vaccination
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 1
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 1 were included in this outcome measure. AEs included both serious AEs (SAEs) and non-SAEs.
Time frame: From Day 1 through 1 Month after Study Vaccination 1 (Vaccination on Day 1, Month 0)
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 2
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 2 were included in this outcome measure. AEs included both SAEs and non-SAEs.
Time frame: From Day 1 through 1 Month after Study Vaccination 2 (Vaccination on Day 1, Month 2)
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 3
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 3 were included in this outcome measure. AEs included both SAEs and non-SAEs.
Time frame: From Day 1 through 1 Month after Study Vaccination 3 (Vaccination on Day 1, Month 6)
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 4 were included in this outcome measure. AEs included both SAEs and non-SAEs.
Time frame: From Day 1 through 1 Month after Study Vaccination 4 (Vaccination on Day 1, Month 18)
Percentage of Participants With AEs Through 1 Month Following Any Study Vaccination
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after any dose were included in this outcome measure.
Time frame: From Day 1 through 1 Month after any study vaccination
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. NDCMCs included conditions that were undiagnosed prior to study entry (diagnosed while in the study and confirmed not to be a preexisting condition) and that were not considered temporary conditions based upon the expected natural history of the condition. An NDCMC was not reported on AE CRF.
Time frame: Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)
Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other important medical event.
Time frame: Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)
A total of 3646 participants were enrolled, of which 3547 participants were randomized.
| Milestone | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Started | 1432 | 475 | 1221 | 419 |
| Vaccinated | 1429 | 467 | 1219 | 418 |
| Completed | 1209 | 389 | 997 | 350 |
| Not completed | 223 | 86 | 224 | 69 |
| Withdrew: Physician decision | 9 | 3 | 5 | 2 |
| Withdrew: Withdrawal by subject | 45 | 12 | 49 | 16 |
| Withdrew: No longer met eligibility criteria | 3 | 0 | 7 | 1 |
| Withdrew: Withdrawal by parent or guardian | 50 | 18 | 42 | 11 |
| Withdrew: Lost to follow-up | 96 | 43 | 106 | 34 |
| Withdrew: Medication error without associated adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Other | 5 | 1 | 3 | 0 |
| Withdrew: Randomized but not treated | 3 | 8 | 2 | 1 |
| Withdrew: Adverse event | 10 | 1 | 10 | 4 |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the electronic dairy (e-diary) or by investigators in case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on Center for Biologics Evaluation and Research (CBER) toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1 | 80.8 (78.6 to 82.8) | 34.8 (30.4 to 39.4) | 80.6 (78.3 to 82.8) | 14.6 (11.4 to 18.4) |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 2 | 72.6 (70.0 to 75.0) | 29.0 (24.8 to 33.5) | 71.4 (68.6 to 74.0) | 11.7 (8.6 to 15.3) |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 3 | 73.5 (70.9 to 75.9) | 25.1 (20.8 to 29.7) | 69.6 (66.8 to 72.4) | 9.7 (6.9 to 13.1) |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose) | 77.0 (74.5 to 79.4) | 24.7 (20.5 to 29.4) | 71.6 (68.7 to 74.4) | 11.7 (8.6 to 15.6) |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study Vaccination | 88.3 (86.5 to 89.9) | 56.0 (51.4 to 60.6) | 90.0 (88.2 to 91.6) | 31.6 (27.1 to 36.3) |
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 1 | 56.0 (53.3 to 58.6) | 41.0 (36.5 to 45.7) | 62.2 (59.4 to 64.9) | 48.8 (43.8 to 53.7) |
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 2 | 48.1 (45.3 to 50.8) | 30.2 (25.9 to 34.8) | 55.3 (52.3 to 58.2) | 31.6 (27.0 to 36.5) |
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 3 | 47.5 (44.6 to 50.3) | 27.6 (23.2 to 32.3) | 51.6 (48.5 to 54.6) | 26.1 (21.7 to 30.9) |
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose) | 53.5 (50.6 to 56.4) | 28.1 (23.7 to 32.9) | 54.8 (51.6 to 57.9) | 28.4 (23.7 to 33.4) |
Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study Vaccination | 77.8 (75.5 to 79.9) | 60.1 (55.5 to 64.6) | 82.1 (79.8 to 84.2) | 63.1 (58.3 to 67.8) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 1 were included in this outcome measure. AEs included both serious AEs (SAEs) and non-SAEs.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With AEs Through 1 Month Following Study Vaccination 1 | 3.4 (2.6 to 4.5) | 3.0 (1.6 to 5.0) | 3.1 (2.2 to 4.3) | 4.5 (2.8 to 7.0) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 2 were included in this outcome measure. AEs included both SAEs and non-SAEs.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With AEs Through 1 Month Following Study Vaccination 2 | 2.4 (1.7 to 3.4) | 2.2 (1.1 to 4.0) | 1.5 (0.9 to 2.4) | 2.2 (1.0 to 4.2) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 3 were included in this outcome measure. AEs included both SAEs and non-SAEs.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With AEs Through 1 Month Following Study Vaccination 3 | 4.6 (3.5 to 5.8) | 3.5 (2.0 to 5.7) | 4.6 (3.5 to 6.0) | 4.3 (2.5 to 6.8) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 4 were included in this outcome measure. AEs included both SAEs and non-SAEs.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose) | 4.1 (3.0 to 5.3) | 2.5 (1.2 to 4.6) | 4.1 (3.0 to 5.5) | 4.7 (2.8 to 7.5) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after any dose were included in this outcome measure.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With AEs Through 1 Month Following Any Study Vaccination | 11.7 (10.1 to 13.5) | 8.6 (6.2 to 11.5) | 11.2 (9.5 to 13.1) | 12.2 (9.2 to 15.7) |
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. NDCMCs included conditions that were undiagnosed prior to study entry (diagnosed while in the study and confirmed not to be a preexisting condition) and that were not considered temporary conditions based upon the expected natural history of the condition. An NDCMC was not reported on AE CRF.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study | 2.7 (1.9 to 3.7) | 1.9 (0.9 to 3.6) | 2.1 (1.4 to 3.1) | 3.3 (1.8 to 5.6) |
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other important medical event.
| Percentage of participants | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years |
|---|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study | 1.0 (0.6 to 1.7) | 0.9 (0.2 to 2.2) | 2.2 (1.5 to 3.2) | 2.4 (1.2 to 4.4) |
Collected over Local reactions and systemic events: Day 1 to Day 7 after each study vaccination; SAEs, All-cause mortality: Throughout the study (from study Vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months); Other AEs: From Day 1 through 1 Month after any study vaccination. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VLA15: 5 to 11 Years | 0/1,429 (0%) | 15/1,429 (1%) | 1,290/1,429 (90.3%) |
| Placebo: 5 to 11 Years | 0/467 (0%) | 4/467 (0.9%) | 341/467 (73%) |
| VLA15: 12 to 17 Years | 0/1,219 (0%) | 27/1,219 (2.2%) | 1,121/1,219 (92%) |
| Placebo: 12 to 17 Years | 1/418 (0.2%) | 10/418 (2.4%) | 295/418 (70.6%) |
| VLA15: Overall | 0/2,648 (0%) | 42/2,648 (1.6%) | 2,411/2,648 (91%) |
| Placebo: Overall | 1/885 (0.1%) | 14/885 (1.6%) | 636/885 (71.9%) |
| Event | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years | VLA15: Overall | Placebo: Overall |
|---|---|---|---|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/1429 | 0/467 | 0/1219 | 2/418 | 0/2648 | 2/885 |
| Suicidal ideationPsychiatric disorders | 0/1429 | 1/467 | 3/1219 | 0/418 | 3/2648 | 1/885 |
| Mycoplasma infectionInfections and infestations | 0/1429 | 0/467 | 0/1219 | 1/418 | 0/2648 | 1/885 |
| OsteomyelitisInfections and infestations | 0/1429 | 0/467 | 0/1219 | 1/418 | 0/2648 | 1/885 |
| PharyngitisInfections and infestations | 0/1429 | 0/467 | 0/1219 | 1/418 | 0/2648 | 1/885 |
| TonsillitisInfections and infestations | 0/1429 | 0/467 | 0/1219 | 1/418 | 0/2648 | 1/885 |
| Tibia fractureInjury, poisoning and procedural complications | 0/1429 | 0/467 | 1/1219 | 1/418 | 1/2648 | 1/885 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 2/1429 | 0/467 | 0/1219 | 1/418 | 2/2648 | 1/885 |
| EpilepsyNervous system disorders | 0/1429 | 0/467 | 0/1219 | 1/418 | 0/2648 | 1/885 |
| Drug abusePsychiatric disorders | 0/1429 | 0/467 | 0/1219 | 1/418 | 0/2648 | 1/885 |
| Event | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years | VLA15: Overall | Placebo: Overall |
|---|---|---|---|---|---|---|
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 1245/1429 | 250/467 | 1084/1219 | 130/418 | 2329/2648 | 380/885 |
| Fatigue (FATIGUE)General disorders | 875/1429 | 219/467 | 769/1219 | 193/418 | 1644/2648 | 412/885 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 891/1429 | 76/467 | 305/1219 | 12/418 | 1196/2648 | 88/885 |
| Headache (HEADACHE)Nervous system disorders | 750/1429 | 192/467 | 734/1219 | 180/418 | 1484/2648 | 372/885 |
| Swelling (SWELLING)General disorders | 752/1429 | 45/467 | 277/1219 | 7/418 | 1029/2648 | 52/885 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 717/1429 | 112/467 | 637/1219 | 110/418 | 1354/2648 | 222/885 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 375/1429 | 64/467 | 353/1219 | 65/418 | 728/2648 | 129/885 |
| Pyrexia (FEVER)General disorders | 193/1429 | 29/467 | 89/1219 | 19/418 | 282/2648 | 48/885 |
| Upper respiratory tract infectionInfections and infestations | 31/1429 | 13/467 | 24/1219 | 16/418 | 55/2648 | 29/885 |
| Pharyngitis streptococcalInfections and infestations | 47/1429 | 14/467 | 12/1219 | 5/418 | 59/2648 | 19/885 |
Safety population included all enrolled participants who received at least 1 dose of the study intervention.
| Age, Continuous(Years) | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years | Total |
|---|---|---|---|---|---|
| Mean | 8.2 ± 2.0 | 8.2 ± 2.0 | 14.3 ± 1.7 | 14.3 ± 1.7 | 11 ± 3.5 |
| Sex: Female, Male(Participants) | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years | Total |
|---|---|---|---|---|---|
| Female | 653 | 214 | 596 | 182 | 1645 |
| Male | 776 | 253 | 623 | 236 | 1888 |
| Ethnicity (NIH/OMB)(Participants) | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 240 | 75 | 268 | 90 | 673 |
| Not Hispanic or Latino | 1181 | 391 | 944 | 327 | 2843 |
| Unknown or Not Reported | 8 | 1 | 7 | 1 | 17 |
| Race (NIH/OMB)(Participants) | VLA15: 5 to 11 Years | Placebo: 5 to 11 Years | VLA15: 12 to 17 Years | Placebo: 12 to 17 Years | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 5 | 0 | 9 |
| Asian | 32 | 12 | 27 | 12 | 83 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 | 0 | 4 |
| Black or African American | 262 | 99 | 208 | 72 | 641 |
| White | 1081 | 342 | 947 | 320 | 2690 |
| More than one race | 37 | 8 | 20 | 9 | 74 |
| Unknown or Not Reported | 13 | 4 | 10 | 5 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2022 to primary completion in Jul 2025, 31 months.
Results were first posted in May 2026, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VLA15